ANTI-TUMOR AUTOVACCINE IMPROVES EFFICACY OF TREATMENT OF MALIGNANT BRAIN TUMORS

An anti-tumor autovaccine produced with the help of cytotoxic lectin from В. subtilis, B-7025 and used in combined treatment of malignant brain tumors (45 patients) is shown to improve 1–4 year survival and significantly (p < 0.05) increase the life span. The vaccine increases the median survival rate by a factor of 1.6–1.9 (depending on the schedule) and improves the quality of life. During vaccine therapy, it is of clinical value to monitor the contents of CD 3+, CD 4+, CD 8+, immunoregulatory index, IgG concentration and phagocitic number, as well as (to a smaller extent) IgA concentration and phagocytic index. A correlation is established between immunologic indices and individual life expectancy of the patients.